5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Efficacy and Safety of Remimazolam Besylate Combined with Esketamine for Outpatient Colonoscopy: A Prospective, Randomized, Controlled Clinical Trial

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          Evaluate the efficacy and safety of remimazolam besylate combined with esketamine for outpatient colonoscopy.

          Patients and methods

          A total of 150 outpatients undergoing colonoscopy were randomized into two groups. A MOAA/S score ≤3 was maintained. The primary outcome was the rate of successful colonoscopy completion. Time indicators, hemodynamic parameters, the consumption of lidocaine, esketamine, propofol and remimazolam besylate, MOAA/S scores and bispectral index (BIS) values, the lowest SpO 2, body movement, the use of rescue medication, endoscopist and patient satisfaction, recall of the procedure, mini-mental state examination (MMSE), fatigue level and adverse events were recorded.

          Results

          Procedure completion was equivalent between groups ( P > 0.05). Both induction and awakening times were significantly shorter in the P group ( P < 0.05). There were no significant differences in colonoscopy time and discharge time ( P > 0.05). The lowest SpO 2 was significantly lower in the P group, while the level of fatigue was higher ( P < 0.05). Patient satisfaction was significantly higher in the R group ( P < 0.05). Endoscopist satisfaction was significantly higher in the P group ( P < 0.05). There were no significant differences in both systolic and diastolic blood pressure between groups except at T5 and T6 ( P > 0.05). Both HR and RR were significantly lower in the P group from T3 to T5 ( P < 0.05). BIS values were significantly lower in the P group from T3 to T5, while MOAA/S was significantly lower in the P group at T3 and T4 ( P < 0.05). Pain on injection was significantly higher in the P group ( P < 0.05).

          Conclusion

          Remimazolam besylate has a similar efficacy to propofol when combined with subanesthetic doses of esketamine during outpatient colonoscopy. Remimazolam besylate combined with esketamine resulted in less injection pain and more stable hemodynamics, although it prolonged induction and awakening time.

          Related collections

          Most cited references47

          • Record: found
          • Abstract: found
          • Article: not found

          Remimazolam tosilate in upper gastrointestinal endoscopy: A multicenter, randomized, non‐inferiority, phase III trial

          Remimazolam tosilate (RT) is a new short-acting GABA(A) receptor agonist, having potential to be an effective option for procedural sedation. Here, we aimed to compare the efficacy and safety of RT with propofol in patients undergoing upper gastrointestinal endoscopy.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Pharmacokinetics and Safety of Esketamine in Chinese Patients Undergoing Painless Gastroscopy in Comparison with Ketamine: A Randomized, Open-Label Clinical Study

            Purpose To assess the pharmacokinetics and safety of pure S-ketamine (esketamine) in Chinese patients undergoing painless gastroscopy and evaluate the potential advantage of esketamine in clinical treatment compared with racemate ketamine hydrochloride injection. Patients and methods A randomized, open-label, parallel-controlled, Phase I study was performed with 32 patients undergoing painless gastroscopy. Patients received a single dose of esketamine (0.5 mg/kg) or racemic ketamine (1 mg/kg, esketamine:R-ketamine=1:1), injected in 10 s. Blood samples were collected for pharmacokinetic analysis. The concentrations of esketamine, R-ketamine, S-norketamine, and R-norketamine were measured with a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) method. Results After administering a single dose of esketamine and racemate ketamine, the pharmacokinetics parameters of esketamine and S-norketamine are both similar in treatment groups. The clearance of esketamine in two groups was 18.1±3.2 and 18.4±3.4 mL/min•kg, respectively. However, in the ketamine group, esketamine has a larger clearance than R-ketamine (18.4±3.4 mL/min·kg vs 15.8±3.1 mL/min·kg, P<0.001). Further analysis showed that gender did not affect the pharmacokinetics of esketamine and racemate ketamine. Regarding the safety of esketamine and racemate ketamine, no serious adverse events were observed during treatment, and the incidences of adverse events were 75.0% (esketamine) and 87.5% (racemate ketamine). The main adverse reactions were dizziness, agitation, nausea, vomiting, headache, and fatigue. However, compared with racemic ketamine, esketamine offers a shorter recovery time (9 mins vs. 13 mins, P<0.05) and orientation recovery time (11.5 mins vs. 17 mins, P<0.05) after short anesthesia. Conclusion Esketamine administration as a single dose of 0.5 mg/kg was generally safe and tolerated in patients undergoing painless gastroscopy. In terms of anesthesia, a relatively small dose of esketamine can be used instead of racemate ketamine for routine treatment without consideration of gender differences.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Remimazolam for anaesthesia or sedation

                Bookmark

                Author and article information

                Journal
                Drug Des Devel Ther
                Drug Des Devel Ther
                dddt
                Drug Design, Development and Therapy
                Dove
                1177-8881
                18 September 2023
                2023
                : 17
                : 2875-2887
                Affiliations
                [1 ]Department of Anaesthesiology, Ordos Central Hospital , Ordos, Inner Mongolia Autonomous Region, People’s Republic of China
                Author notes
                Correspondence: Zaijun Hao, Department of Anesthesiology, Ordos Central Hospital , Ordos, Inner Mongolia Autonomous Region, 017000, People’s Republic of China, Tel/Fax +8615204778880, Email dengdairy@126.com
                Article
                425860
                10.2147/DDDT.S425860
                10516197
                37746114
                0a95ce47-20ee-4343-9e59-96780afec99a
                © 2023 Li et al.

                This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

                History
                : 03 July 2023
                : 10 September 2023
                Page count
                Figures: 5, Tables: 11, References: 47, Pages: 13
                Funding
                Funded by: Key research and development (R&D) Plan Project in Ordos City;
                Key research and development (R&D) Plan Project in Ordos City (NO.YF20232339).
                Categories
                Original Research

                Pharmacology & Pharmaceutical medicine
                remimazolam besylate,propofol,esketamine,colonoscopy
                Pharmacology & Pharmaceutical medicine
                remimazolam besylate, propofol, esketamine, colonoscopy

                Comments

                Comment on this article